Innovacare has been an important name in the health industry since its inception, and recent changes in leadership have only led to further innovations in this field. When an already important organization acquires the talents of experts like Penelope Kokkinides. Penelope’s addition to the company was announced in July of 2016, at which time Rick Shinto was already the President and CEO of Innovacare.
Rick Shinto brought 20 years of experience to Innovacare, having been central in bringing medical provider networks to Puerto Rico. He’s driven by his desire to increase awareness of health care and ensuring that there is support for the medical community, including patients and their families. Through this philosophy, he sought to build a culture for both employees and patients that would result in open access to caring that lasts a lifetime. His dedication to these principles brought him to receive the Access to Caring Award during the “Tribute to Caring” gala held by Western University Health Sciences. This same dedication had won him the “Young Entrepreneur of The Year” award during his time with Aveta, Inc.
Penelope Kokkinides was added to the company in June of 2016, bringing her own twenty years of experience in handling government programs, as well as having significant time with the managed care industry. Given Innovacare’s goals being centered on developing new programs to ensure accessibility, her background in creating efficient health care processes and clinical programs are going to be essential to Innovacare’s future. Her background is extensive, including time spent with Centerlight Healthcare, Touchstone Health, AmeriChoice, and UnitedHealth group have left her well prepared for the next steps in Innovacare’s future.
Know more: http://vizualize.me/penelopekokkinides
Innovacare’s direction for the future was immediately evident following the addition of Penelope and, earlier, Rick Shinto. Just two months later Innovacare announced its participation in LAN, the Health Care Payment Learning and Action Network with “goals of tying 30 percent of all U.S. health care payments to alternative payment methods.” With an additional purpose of ensuring that in the future providers start seeing payments based not simply on providing services, but on the quality of that care, changing the focus from how much care a patient receives, to the quality of care received by that patient. Visit Penelope’s website at penelopekokkinides.com
With such incredible talent being brought to the board, the future of Innovacare is bright, and we continue to look forward to seeing new and innovative concepts in managed health care coming from them.
Mikhail Blagosklonny is a distinguished researcher and oncology professor. He studied at the First Pavlov State Medical University where he earned a Master’s degree in Internal Medicine. Blagosklonny also has a Doctorate in Cardiology and Experimental Medicine from the University. He moved to the US to join the New York Medical College in Valhalla, NY as an associate professor. Mikhail was hired as a senior scientist at the Ordway Research Institute after college. Mikhail worked there for seven years until he joined the Roswell Park Cancer Institute. Mikhail is an oncology professor at the institute. He collaborates with most of his colleagues on the research that he does. Visit ResearchGate to keep up to date with Mikhail’s latest work.
Mikhail is a prolific researcher and an active member of the scientific community. His research focuses on cancer, targeted cancer therapies, anti-aging techniques, and the mechanisms of aging. A few of the techniques that he uses include tumor suppression, selective protection, signal transduction, and apoptosis. Mikhail published a paper on the possible role of TOR signaling in the development of cancer and aging. He identified that the overdevelopment of cells fundamentally caused cancer and aging. Mikhail discovered that cancer was a sign of aging because they were related. He proposed that TOR signaling could be used to delay cancer. It could also delay aging. There had been a lot of research on cancer at the time, but very little was being done about aging because researchers did not understand it fully. His research veered into cancer treatment and uncovered the role of rapamycin.
Rapamycin is a cancer treatment drug that works by preventing or delaying its formation in the body. This means that it prevents the rapid development of cells that fundamentally delays aging. Mikhail became one of the first advocates of rapamycin as an anti-ageing drug after his discovery. His theory was validated when a variant of Rapamycin known as Everolimus improved immunity at the end of 2014. Mikhail Blagosklonny directed his research into other causes of death even as scientists raced to combat aging and its effects. Mikhail is a founding editor and an editor-in-chief of Oncotarget and Cell Cycle. Oncotarget is a peer-reviewed medical journal that publishes papers on oncology and related fields. It was started in 2010 and has an impact factor of 5. This makes it one of the top medical journals that specialize in cancer treatment and prevention. The journal has improved the fight against cancer because it is open access and is released online each week. This has improved the impact of research and allows discoveries to be shared widely. It is important to note that Mikhail is a member of the editorial board of Cell Death and Differentiation. View Mikhail’s profile on Google Scholar